Status:
TERMINATED
Comparison of Lower-risk MDS Patients With and Without Improvements in Fatigue Following Blood Transfusion Therapy
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
Jean Monnet University
Institut de Cancérologie de la Loire
Conditions:
Myelodysplatic Syndromes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
At present, it is unclear why some myelodysplastic patients (MDS) receiving blood transfusion therapy exhibit an increase in Hemoglobin (Hb) without a concurrent improvement in fatigue. Research is th...
Detailed Description
One hypothesis is that patients who exhibited persistent fatigue following a blood- transfusion- induced increase in Hb have an impaired ability to utilize oxygen at the peripheral level. This could b...
Eligibility Criteria
Inclusion
- Patient affiliated to a social security regimen or beneficiary of the same
- Signed written informed consent form
- Patient, ≥ 18 years-old, with established diagnosis of myelodysplastic syndrome with low or intermediate-1 risk cytogenetic profile
- FACIT-F score ≤ 34,
- Indication of blood transfusion.
Exclusion
- Contra-indication to experimental procedures and/or physical exercise,
- Concomitant cancer diagnosis,
- Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
- Refusing participation.
Key Trial Info
Start Date :
October 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 20 2020
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04103359
Start Date
October 20 2020
End Date
October 20 2020
Last Update
May 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055